To elucidate the role of tumor mutations in the development of acquired resistance to PARP inhibitors and to screen for specific mutational markers associated with resistance, we examined the mutation profiles in cfDNA of ovarian cancer patients during Olaparib maintenance therapy [17]. This evidence concerns the gene PARP1 and ovarian carcinoma.